Highlights: October 2026 NIH Office of AIDS Research Advisory Council Meeting
Strategic planning, healthy aging, whole person health, and community partnerships in HIV research
The National Institutes of Health (NIH) Office of AIDS Research Advisory Council (OARAC) convened its 73rd meeting virtually on October 22.
OARAC provides advice to the NIH Office of AIDS Research (OAR) on the planning, coordination, and evaluation of research and other HIV-related activities conducted or supported by NIH.
Key meeting highlights included the recently published FY 2026-2030 NIH Strategic Plan for HIV and HIV-Related Research; updates on OAR programs and funding opportunities; OAR’s HIV and Women focus area; and a scientific session on healthy aging, HIV-associated co-occurring conditions, whole person health, and lifetime survivors (Dandelions). The meeting also included an update on the Community Partnerships and Engagement (COPE) working group, reports from NIH advisory council representatives, and updates to the Adult and Adolescent Antiretroviral Guidelines.
Report: Office of AIDS Research Director
Geri R. Donenberg, Ph.D., Associate Director for AIDS Research and Director, OAR, NIH
Dr. Donenberg reviewed OAR’s progress since the June 2026 OARAC meeting. The FY 2026-2030 NIH Strategic Plan for HIV and HIV-Related Research has been published, and ongoing activities include an HIV portfolio review following OAR’s exercise of transfer authority in FY 2026, exploring broader access to T32 training opportunities, tracking HIV-related K awards, and planning a future presentation on the PF5 mechanism for international research.
Dr. Donenberg highlighted the FY 2027 NIH HIV/AIDS Professional Judgment Budget (PJ), which identifies five areas of scientific opportunity: implementation science (IS) to end the epidemic; new technologies for self-testing and multiplex testing; HIV-related co-occurring conditions; cure research; and data sharing and harmonization. The PJ estimates that an additional $1.059 billion would be needed to expand HIV research, a 32 percent increase over the FY 2026-enacted HIV research budget of $3.294 billion.
OAR also reported new and continuing research opportunities, including an R61/R33 funding opportunity supporting large-scale IS; renewal of the Centers for AIDS Research (CFAR) and Developmental CFAR program; and a new Highlighted Topic (HT) on interdisciplinary research addressing HIV-associated co-occurring conditions. OAR also selected 35 Phase I winners from 116 eligible submissions to its ARISE-HIV LAUNCH (Access, Delivery, Engagement, and Retention for Long-Acting HIV Prevention and Treatment in the United States) Challenge.
Recent OAR scientific and community engagement activities included symposia and workshops, site visits and listening sessions, and participation in national and international HIV meetings. Themes emerging from these engagements include community capacity and ownership, research infrastructure, communication and dissemination, workforce development, sustainability and de-implementation, whole person health, and population-specific considerations.
Council members emphasized the urgency of releasing funding opportunities for the HIV clinical trials networks and encouraged continued opportunities for early career investigators, NIH support across the full spectrum of HIV science, and mechanisms to move promising discoveries toward clinical testing.
FY 2026-2030 NIH Strategic Plan for HIV and HIV-Related Research
Rachel Anderson, Ph.D., Senior Policy Advisor and Acting Chief of Staff, OAR, NIH
Dr. Anderson presented the newly published FY 2026-2030 NIH Strategic Plan for HIV and HIV-Related Research , which was informed by NIH input, portfolio analyses, listening sessions, and workshops, Requests for Information, and OARAC recommendations.
The Plan is grounded in three foundational principles: comprehensive, multidisciplinary research; population-focused health; and multisectoral partnerships. Its overarching priority is accelerating IS to achieve HIV epidemic control while maintaining NIH’s commitment to the full research-to-practice continuum. Its research goal encompasses fundamental, preclinical, intervention, and IS research; its capacity goal addresses workforce, infrastructure, methods, and technologies; and its operational goal focuses on effective stewardship of NIH’s HIV research investment.
Council members recommended an annual mechanism for demonstrating implementation of the Plan by connecting prior-year funding, current HTs, and future PJ priorities. Members also emphasized continued support for fundamental and preclinical research and requested greater clarity about NIH’s commitment to international research.
HIV & Women Focus Area: Connecting Whole Person Health and Syndemics
Elizabeth Barr, Ph.D., Senior Science Advisor, OAR, NIH
Dr. Barr highlighted persistent research and care challenges for women with HIV across the life course, including social and contextual factors, biological and clinical considerations, HIV-associated co-occurring conditions, and evidence gaps resulting in part from women being understudied in HIV research.
NIH investment at the intersection of HIV and women’s health decreased from approximately $334 million in FY 2024 to $308 million in FY 2025. OAR and the NIH Office of Research on Women’s Health have established a joint working group with representatives from 25 NIH institutes, centers, and offices.
OAR will emphasize syndemic approaches to HIV and women’s health in 2026-2027. In FY 2025, 38 percent of NIH HIV projects addressed co-occurring conditions and 13 percent were categorized as women’s health research, but only six percent addressed both. Planned activities include a workshop on integrated HIV care for women and a sponsored journal supplement examining women and HIV through a syndemic lens.
Scientific Session: Healthy Aging, Comorbidities, and Whole Person Health
A Lifetime Perspective: Centering an Overlooked Generation of People Living with HIV
Grissel Granados, M.S.W., Board Chair, Positive Women’s Network USA, Program Development Coordinator, University of California, Irvine Chao Family Comprehensive Cancer Center, Office of Community Outreach & Engagement
Ms. Granados discussed research needs of lifetime survivors (Dandelions)—people who acquired HIV at birth or in early childhood. Unanswered questions include the effects of lifelong HIV and antiretroviral exposure, aging, mental health, sexual and reproductive health, neurocognition, and transitions across stages of care. Recommendations included recognizing lifetime survivors as a distinct population in NIH research priorities, meaningfully involving lifetime survivors throughout research, and conducting a portfolio analysis to identify gaps.
A Clearer Vision for Brain Health: How Neuroimaging Maps Heterogeneity in HIV
Beau Ances, M.D., Ph.D., Professor of Neurology, Washington University, St. Louis
Dr. Ances described how neuroimaging can characterize the varied effects of HIV, aging, co-occurring conditions, inflammation, and social and environmental factors on brain health. Approaches combining imaging, cognitive measures, biomarkers, and machine learning may help identify biologically informed subtypes and “treatable traits,” supporting more individualized interventions and translation of neuroHIV research into clinical practice.
Advancing Population Health Through Tailored Dietary Interventions Across Diverse Populations
Sabrina E. Noel, Ph.D., R.D., Associate Professor, Department of Public Health, Director, Center for Population Health, Director, Health Assessment Laboratory, Sc.D. Graduate Program Coordinator, Zuckerberg College of Health Sciences, University of Massachusetts Lowell
Dr. Noel discussed nutrition as a modifiable contributor to cardiometabolic health and healthy aging among people with HIV. She highlighted increased cardiometabolic risk, poorer dietary quality, and food insecurity. She described Project GLOW (Glucose Levels for Optimizing Wellness for People Living with HIV), a pilot study of culturally tailored meal kits and nutrition education for adults with HIV who experience food insecurity and have prediabetes or insulin resistance. The intervention aims to build sustainable healthy-eating skills while accounting for economic, cultural, and environmental barriers.
Considerations for Long-Term Survivors
Jeff Taylor, Executive Director, HIV+ Aging Research Project-Palm Springs
Mr. Taylor discussed medical and psychosocial needs of long-term survivors, including multimorbidity, inflammation, treatment legacy effects, social isolation, mental health concerns, and fragmented healthcare. Recommendations included removing arbitrary upper age limits from studies, sustaining longitudinal cohorts, ensuring trial populations reflect current and projected age distributions, strengthening research on geriatric models of HIV care, and expanding research beyond viral suppression to address inflammation, quality of life, and healthy aging.
Council discussions reinforced the importance of whole person approaches accounting for HIV, aging, co-occurring conditions, social and environmental conditions, and individual life histories. Members identified gaps related to brain health, lifetime survivors, elite controllers (people who naturally control viral load without treatment), sustainable nutrition interventions, pharmacy access, and representation of older adults in research. Members also emphasized the value of international collaborations for understanding lifetime survivors and aging with HIV.
Report: COPE Working Group
Elizabeth Barr, Ph.D., Senior Science Advisor, OAR, NIH
Dr. Barr provided an update on the OARAC COPE working group, established to advise OARAC on community priorities for NIH HIV research. Its inaugural membership includes OARAC members and external partners, with plans to expand through a staged process to reflect the breadth of communities affected by HIV.
Council members emphasized that contemporary community engagement extends beyond traditional community advisory boards and encouraged approaches that enable community members to serve as subject matter experts and research partners while building community capacity and supporting meaningful participation throughout the research process.
Updates: NIH Advisory Council Representatives
Hiroko Iida, D.D.S., M.P.H., Director, Dental, Oral, Craniofacial Health Disparities Program, HIV/AIDS Program, National Institute of Dental and Craniofacial Research (NIDCR), NIH
Robert Eisinger, Ph.D., Acting Director, Division of AIDS, National Advisory Allergy and Infectious Disease Council, National Institute of Allergy and Infectious Diseases (NIAID), NIH
Jennifer Havens, Ph.D., M.P.H., Professor, Department of Behavioral Science, University of Kentucky College of Medicine, National Advisory Council on Drug Abuse, National Institute on Drug Abuse (NIDA), NIH
David Chang, Ph.D., Supervisory Health Science Administrator, Senior Science Advisor, NIH HIV/AIDS Executive Committee (NAEC), OAR, NIH
Dr. Iida described NIDCR-supported research connecting oral and systemic health, including IS approaches that integrate HIV prevention and care into dental settings. Dr. Eisinger provided an update from NIAID on HIV research and funding activities, including the status of programs supporting HIV clinical research and the HIV research infrastructure. Dr. Havens highlighted NIDA’s planned second phase of the SCORCH (Single Cell Opioid Responses in the Context of HIV) program, which will continue research on the effects of opioids and HIV at the single-cell level. Ms. Herrera, presenting on behalf of Dr. Chang, provided an update from the NAEC on trans-NIH coordination of HIV research priorities and activities across NIH institutes, centers, and offices.
Updates: HIV Clinical Guidelines Working Groups of OARAC
Safia Kuriakose, Pharm.D., Senior Pharmacist, Laboratory of Immunoregulation and Infectious Diseases (LIRID), Clinical Research Directorate (CRD), Frederick National Laboratory for Cancer Research, NIH Adult and Adolescent Antiretroviral Guidelines
Dr. Kuriakose reviewed September 2026 updates to the Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Changes included a new section on principles of antiretroviral therapy (ART); recommending dolutegravir/lamivudine regardless of baseline plasma HIV viral load; information on the newly approved doravirine/islatravir regimen; expanded recommendations for hepatitis B and HIV co-occurrence; and additional guidance on interruptions of oral and long-acting ART. Additional updates are expected to address FDA approval of bictegravir/lenacapavir, cardiovascular complications and lipid monitoring, and related drug and dosing information.
Public Comment | Closing Remarks
Melissa Herrera, M.P.H., OARAC Executive Secretary, Public Health Analyst, OAR, NIH
Geri R. Donenberg, Ph.D., Associate Director for AIDS Research and Director, OAR, NIH
OARAC received six public comments at least 48 hours before the meeting. Several commenters urged immediate release of the NIAID HIV clinical trials networks funding opportunity and bridge funding for CFARs, citing risks to research continuity, expertise, participant engagement, community trust, mentorship, and workforce development.
Commenters also emphasized meaningful inclusion of lifetime survivors in HIV research, including women and people younger than age 50; sustained federal investment across biomedical, clinical, behavioral, and IS; continued research on prevention and care engagement, adherence, retention, and stigma reduction; and preservation of scientific expertise in funding decisions.
An independent patient-led researcher proposed an integrated HIV cure research framework examining interactions among reservoir biology, immune function, metabolism, neuroimmune signaling, the microbiome, and molecularly characterized natural compounds, emphasizing staged testing and investigation alongside suppressive ART rather than replacing it with unproven interventions.
Additional comments received through November 19 will be included in the meeting minutes.
The full meeting will be available on NIH VideoCast, and meeting minutes will be posted on the OAR website.
The next OARAC meeting will be on February 25, 2027. OARAC welcomes public comments via email to [email protected].
This page last reviewed on November 19, 2026